MST1 selective inhibitor Xmu-mp-1 ameliorates neuropathological changes in a rat model of sporadic Alzheimer’s Disease by modulating Hippo-Wnt signaling crosstalk
Apoptosis · 2024
DOI: 10.1007/s10495-024-01975-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Apoptosis, 2024. Verfasst von Manas Ranjan Sahu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India. Hauptthemen laut MEDLINE: Alzheimer Disease, Apoptosis, Disease Models, Animal, Wnt Signaling Pathway. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 92 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD), the most prevalent form of dementia, is characterized by progressive cognitive impairment accompanied by aberrant neuronal apoptosis. Reports suggest that the pro-apoptotic mammalian set20-like kinase 1/2 (MST1/2) instigates neuronal apoptosis via activating the Hippo signaling pathway under various stress conditions, including AD. However, whether inhibiting MST1/2 has any therapeutic benefits in AD remains unknown. Thus, we tested the therapeutic effects of intervening MST1/2 activation via the pharmacological inhibitor Xmu-mp-1 in a sporadic AD rat model. Sporadic AD was established in adult rats by intracerebroventricular streptozotocin (ICV-STZ) injection (3 mg/kg body weight). Xmu-mp-1 (0.5 mg/kg/body weight) was administered once every 48 h for two weeks, and Donepezil (5 mg/kg body weight) was used as a reference standard drug. The therapeutic effects of Xmu-mp-1 on ICV-STZ rats were determined through various behavioral, biochemical, histopathological, and molecular tests. At the behavioral level, Xmu-mp-1 improved cognitive deficits in sporadic AD rats. Further, Xmu-mp-1 treatment reduced STZ-associated tau phosphorylation, amyloid-beta deposition, oxidative stress, neurotoxicity, neuroinflammation, synaptic dysfunction, neuronal apoptosis, and neurodegeneration. Mechanistically, Xmu-mp-1 exerted these neuroprotective actions by inactivating the Hippo signaling while potentiating the Wnt/β-Catenin signaling in the AD rats. Together, the results of the present study provide compelling support that Xmu-mp-1 negated the neuronal dysregulation in the rat model of sporadic AD. Therefore, inhibiting MST/Hippo signaling and modulating its crosstalk with the Wnt/β-Catenin pathway can be a promising alternative treatment strategy against AD pathology. This is the first study providing novel mechanistic insights into the therapeutic use of Xmu-mp-1 in sporadic AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India.
- Laboratory of Cellular and Molecular Neurobiology, School of Life Sciences, Jawaharlal Nehru University, New Delhi, 110067, India. acmondal@mail.jnu.ac.in.
Zitieren
APA
Sahu, M. R., Ahmad, M. H., & Mondal, A. C. (2024). MST1 selective inhibitor Xmu-mp-1 ameliorates neuropathological changes in a rat model of sporadic Alzheimer’s Disease by modulating Hippo-Wnt signaling crosstalk. Apoptosis. https://doi.org/10.1007/s10495-024-01975-0
Vancouver
Sahu MR, Ahmad MH, Mondal AC. MST1 selective inhibitor Xmu-mp-1 ameliorates neuropathological changes in a rat model of sporadic Alzheimer’s Disease by modulating Hippo-Wnt signaling crosstalk. Apoptosis. 2024. doi:10.1007/s10495-024-01975-0
BibTeX
@article{Sahu2024,
author = {Sahu, Manas Ranjan and Ahmad, Mir Hilal and Mondal, Amal Chandra},
title = {MST1 selective inhibitor Xmu-mp-1 ameliorates neuropathological changes in a rat model of sporadic Alzheimer’s Disease by modulating Hippo-Wnt signaling crosstalk},
journal = {Apoptosis},
year = {2024},
doi = {10.1007/s10495-024-01975-0}
}
EUVIMED